The role of biosimilars in value-based oncology care

References

• FrankRGRegulation of follow-on biologicsN Engl J Med2007357984184317761588
   PubMed Web of Science ®Google Scholar
• PasinaLCasadeiGNobiliABiological agents and biosimilars: essential information for the internistEur J Intern Med201633283527342030
   PubMed Web of Science ®Google Scholar
• ZelenetzADAhmedIBraudELNCCN biosimilars white paper: regulatory, scientific, and patient safety perspectivesJ Natl Compr Canc Netw20119Suppl 4S1S22
   PubMed Web of Science ®Google Scholar
• HusIFollow-on biologics in oncology – the need for global and local regulationsContemp Oncol (Pozn)201216646146623788931
   PubMed Web of Science ®Google Scholar
• KuhlmannMCovicAThe protein science of biosimilarsNephrol Dial Transplant200621Suppl 5v4v816959791
   PubMed Web of Science ®Google Scholar
• MorrowTFelconeLHDefining the difference: what makes biologics uniqueBiotechnol Healthc2004142429
   PubMedGoogle Scholar
• BuskeCOguraMKwonHCYoonSWAn introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirementsFuture Oncol20171315s516
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration [webpage on the Internet]Information on Biosimilars2016 https://www.fda.gov/Drugs/Devel-opmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/Accessed May 18, 2017
   Google Scholar
• U.S. Food Drug AdministrationScientific considerations in demonstrating biosimilarity to a reference product: guidance for industry2015 http://www.fda.gov/downloads/DrugsGuidanceCompliance-RegulatoryInformation/Guidances/UCM291128.pdfAccessed May 18, 2017
   Google Scholar
• CamachoLHCurrent status of biosimilars in oncologyDrugs201777998599728477160
   PubMed Web of Science ®Google Scholar
• HealthIMSDevelopments in cancer treatments, market dynamics, patient access and valueGlobal oncology trend report 20152015 http://keionline.org/sites/default/files/IIHI_Oncology_Trend_Report_2015.pdfAccessed May 17, 2017
   Google Scholar
• SullivanRPeppercornJSikoraKDelivering affordable cancer care in high-income countriesLancet Oncol2011121093398021958503
   PubMed Web of Science ®Google Scholar
• ChanDLHSegelovEWongRSEpidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancerCochrane Database Syst Rev20176CD00704728654140
   PubMedGoogle Scholar
• PorterDLLevineBLKalosMBaggAJuneCHChimeric antigen receptor-modified T cells in chronic lymphoid leukemiaN Engl J Med2011365872573321830940
   PubMed Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaAToGA Trial InvestigatorsTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDiaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• ArgirisAHarringtonKJTaharaMEvidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neckFront Oncol201777228536670
   PubMed Web of Science ®Google Scholar
• VansteenkisteJPirkerRMassutiBDouble-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapyJ Natl Cancer Inst200294161211122012189224
   PubMed Web of Science ®Google Scholar
• DammaccoFCastoldiGRodjerSEfficacy of epoetin alfa in the treatment of anaemia of multiple myelomaBr J Haematol2001113117217911328297
   PubMed Web of Science ®Google Scholar
• IconomouGKoutrasARigopoulosAVagenakisAGKalofonosHPEffect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trialJ Pain Symptom Manage200325651251812782431
   PubMed Web of Science ®Google Scholar
• OsterborgABoogaertsMACiminoRRecombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma – a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s LymphomaBlood1996877267526828639883
   PubMed Web of Science ®Google Scholar
• WilsonJYaoGLRafteryJA systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatmentHealth Technol Assess200711131202iiiiv
   PubMed Web of Science ®Google Scholar
• CoiffierBBoogaertsMKaineCImpact of Epoetin Beta Versus Standard Care on Quality of Life in Patients with Malignant Disease6th Congress of the European Haematology AssociationFrankfurt, GermanyJune 2001 Abstract no. 194
   Google Scholar
• INC ResearchThe State of Biosimilars, A FirstWord Perspectives Report Available from: http://www.firstwordplus.com/images/ads/TheStateofBiosimilars.pdfAccessed May 18, 2017
   Google Scholar
• ElkinEBBachPBCancer’s next frontier: addressing high and increasing costsJAMA2010303111086108720233828
   PubMed Web of Science ®Google Scholar
• MariottoABYabroffKRShaoYFeuerEJBrownMLProjections of the cost of cancer care in the United States: 2010-2020J Natl Cancer Inst2011103211712821228314
   PubMed Web of Science ®Google Scholar
• National Cancer Institute [webpage on the Internet]Cancer prevalence and cost of care projections2017 https://costprojections.cancer.gov/Accessed June 26, 2017
   Google Scholar
• SchnipperLEDavidsonNEWollinsDSAmerican Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment optionsJ Clin Oncol201533232563257726101248
   PubMed Web of Science ®Google Scholar
• IMS HealthMedicines use and spending in the USA review of 2015 and outlook to 20202016 https://morningconsult.com/wp-content/uploads/2016/04/IMS-Institute-US-Drug-Spending-2015.pdfAccessed May 17, 2017
   Google Scholar
• IMS HealthTop 20 global products 20152015 http://www.imshealth.com/files/web/Corporate/News/Top-Line%20Market%20Data/Top_20_Global_Products_2015.pdfAccessed May 17, 2017
   Google Scholar
• de SouzaJAYapBJWroblewskiKMeasuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)Cancer2017123347648427716900
   PubMed Web of Science ®Google Scholar
• O’ConnorJMKircherSMde SouzaJAFinancial toxicity in cancer careJ Comm Supp Oncol2016143101106
   Google Scholar
• Casilla-LennonMMChoiSKDealAMFinancial toxicity in bladder cancer patients – reasons for delay in care and effect on quality of lifeJ Urol201819951166117329155338
   PubMedGoogle Scholar
• HuntingtonSFWeissBMVoglDTFinancial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyLancet Haematol2015210e408e41626686042
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyBiosimilars in the EU: information guide for healthcare professionals2017 http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdfAccessed May 24, 2017
   Google Scholar
• SimoensSBiosimilar medicines and cost-effectivenessClinicoecon Outcomes Res20113293621935330
   PubMedGoogle Scholar
• IMS Institute for Healthcare InformaticsDelivering on the potential of biosimilar medicines: the role of functioning competitive markets [updated March 2016]. http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdfAccessed June 14, 2017
   Google Scholar
• European Medicines Agency [webpage on the Internet]European public assessment reports (EPAR) for human medicines: biosimilars2017 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125http://www.ema.europa.eu/ema/index.jsp?mid=WC0b01ac058001d125&searchType=name&taxonomyPath=Diseases&searchGenericType=generics&keyword=Enter+keywords&alreadyLoaded=true&curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&currentCategory=Cancer&treeNumber=&searchTab=&pageNo=2Accessed August 18, 2017
   Google Scholar
• GasconPTeschHVerpoortKClinical experience with Zarzio® in Europe: what have we learned?Supp Care Cancer2013211029252932
   PubMed Web of Science ®Google Scholar
• AraujoFCGoncalvesJFonsecaJEPharmacoeconomics of biosimilars: what is there to gain from them?Curr Rheumatol Rep20161885027402107
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyApplications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use: August 2017EMA/506776/2017 http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/08/WC500233092.pdfAccessed August 18, 2017
   Google Scholar
• Truven Health AnalyticsBiosimilar Market Access, A FirstWord Perspectives ReportTruven Health Analytics, an IBM Company Ann ArborMI, USA102016
   Google Scholar
• Mestre-FerrandizJTowseABerdudMBiosimilars: how can payers get long-term savings?Pharmacoeconomics201634660961626792791
   PubMed Web of Science ®Google Scholar
• Informatics IIfHThe Impact of Biosimilar Competition in EuropeParsippany, NJ52017
   Google Scholar
• AbrahamIHanLSunDMacDonaldKAaproMCost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countriesFuture Oncol20141091599160925145430
   PubMed Web of Science ®Google Scholar
• ManolisCHRajasenanKHarwinWMcClellandSLopesMFarnumCBiosimilars: opportunities to promote optimization through payer and provider collaborationJ Manag Care Spec Pharm201622Suppl 9S3S9
   PubMed Web of Science ®Google Scholar
• FarhatFOthmanAel KarakFKattanJReview and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa regionSpringerplus201651211328090427
   PubMedGoogle Scholar
• BennettCLChenBHermansonTRegulatory and clinical considerations for biosimilar oncology drugsLancet Oncol20141513E594E60525456378
   PubMed Web of Science ®Google Scholar
• GovernmentUSBiologics Price Competition and Innovation Act, sections 7001–7003Public law no. 111-1482009 https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdfAccessed May 18, 2017
   Google Scholar
• USCB OfficeS 1695 Biologics Price Competition and Innovation Act of 20072008 https://www.cbo.gov/publication/41712Accessed June 28, 2017
   Google Scholar
• ChristlLDeisserothA webpage on the InternetDevelopment and approval of biosimilar products2015 http://www.ascopost.com/issues/march-25-2015/development-and-approval-of-biosimilar-products/Accessed May 18, 2017
   Google Scholar
• ChristlLAWoodcockJKozlowskiSBiosimilars: the US regulatory frameworkAnnu Rev Med20176824325427813877
   PubMed Web of Science ®Google Scholar
• NovartisAG [news release] [webpage on the Internet]Sandoz launches Zarxio™ (filgrastim-sndz), the first biosimilar in the United States2015 https://www.novartis.com/news/media-releases/sandoz-launches-zarxiotm-filgrastim-sndz-first-biosimilar-united-statesAccessed June 14, 2017
   Google Scholar
• RaedlerLAZarxio (filgrastim-sndz): first biosimilar approved in the United StatesAm Health Drug Benefits20169 Spec Feature15015427668063
   PubMedGoogle Scholar
• McBrideACampbellKBikkinaMMacDonaldKAbrahamIBaluSCost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaJ Med Econ201720101083109328722494
   PubMed Web of Science ®Google Scholar
• McBrideABaluSCampbellKBikkinaMMacDonaldKAbrahamIExpanded access to cancer treatments from conversion to neutro-penia prophylaxis with biosimilar filgrastim-sndzFuture Oncol201713252285229528870106
   PubMed Web of Science ®Google Scholar
• RED BOOK Online® pricing: Filgrastim, Filgrastim-sndz, Tbo-filgrastim [webpage on the Internet]2017 Truven Health Analytics, an IBM Company2017 https://truvenhealth.com/products/micromedex/product-suites/clinical-knowledge/red-bookAccessed May 24, 2017
   Google Scholar
• Centers for Medicare & Medicaid Services [webpage on the Internet]2017ASP Drug Pricing Files72017 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles.htmlAccessed August 23, 2017
   Google Scholar
• JacobsIEwesuedoRLulaSZacharchukCBiosimilars for the treatment of cancer: a systematic review of published evidenceBioDrugs201731113628078656
   PubMed Web of Science ®Google Scholar
• RugoHSLintonKMCerviPRosenbergJAJacobsI webpage on the InternetA clinician’s guide to biosimilars in oncologyCancer Treat Rev201646737927135548
   PubMed Web of Science ®Google Scholar
• Generics and Biosimilars Initiative (GaBI)Biologicals patent expiries2015 http://www.gabionline.net/Biosimilars/General/Biologicals-patent-expiriesAccessed May 19, 2017
   Google Scholar
• Business Wire [news release] [webpage on the Internet]FDA Advisory Committee recommends approval of Pfizer’s proposed biosimilar to Epogen/Procrit across all indications2017 https://www.biosimilarde-velopment.com/doc/fda-advisory-committee-recommends-approval-of-pfizer-s-proposed-biosimilar-0001Accessed June 26, 2017
   Google Scholar
• FoodUSAdministrationDrugEpoetin Hospira: FDA Advisory Committee Briefing Document2017 https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Oncologic-DrugsAdvisoryCommittee/UCM559968.pdfAccessed August 21, 2017
   Google Scholar
• Generics and Biosimilars Initiative (GaBI) [webpage on the Internet]Apotex petitions FDA over Neulasta biosimilars2017 http://www.gabionline.net/Guidelines/Apotex-petitions-FDA-over-Neulasta-biosimilarsAccessed June 28, 2017
   Google Scholar
• Mylan [news release] [webpage on the Internet]US FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review2017 http://newsroom.mylan.com/2017-02-16-U-S-FDA-Accepts-Biologics-License-Application-BLA-for-Mylan-and-Biocons-Proposed-Biosimilar-Pegfilgrastim-for-ReviewAccessedJune 28, 2017
   Google Scholar
• Generics and Biosimilars Initiative (GaBI) [webpage on the Internet]FDA accepts application for pegfilgrastim biosimilar2015 http://www.gabionline.net/Biosimilars/News/FDA-accepts-application-for-pegfilgrastim-biosimilarAccessed June 28, 2017
   Google Scholar
• Adello Biologics [webpage on the Internet]FDA Accepts Adello’s Biosimilar Biologics License Application (BLA) for a Proposed Filgrastim Biosimilar2017 http://adellobio.com/news/2017/fda-accepts-adellos-biosimilar-biologics-license-application-bla-for-a-proposed-filgrastim-biosimilarAccessed November 20, 2017
   Google Scholar
• Celltrion and Teva Announce U.S.FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® (trastuzumab) [press release] http://phx.corporate-ir.net/phoenix.zhtml?c=251945&p=irol-newsArticle&ID=22901237312017
   Google Scholar
• U.S. FDA accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Trastuzumab [press release] http://investor.mylan.com/news-releases/news-release-details/us-fda-accepts-biologics-license-application-bla-mylan-and1122017
   Google Scholar
• Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food And Drug Administration [press release] https://www.prnewswire.com/news-releases/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-980-to-us-food-and-drug-administration-300496238.html7312017
   Google Scholar
• SorensonCLavezzariGDanielGAdvancing value assessment in the United States: a multistakeholder perspectiveValue Health201720229930728237214
   PubMed Web of Science ®Google Scholar
• SchnipperLEDavidsonNEWollinsDSUpdating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments receivedJ Clin Oncol201634242925293427247218
   PubMed Web of Science ®Google Scholar
• Memorial Sloan Kettering Cancer Center [webpage on the Internet]DrugAbacus methods2017 http://drugpricinglab.org/tools/louisiana-budget-allocator/methods/Accessed May 18, 2017
   Google Scholar
• National Comprehensive Cancer Network [webpage on the Internet]NCCN clinical practice guidelines in oncology (NCCN Guideliness) with NCCN Evidence Blocks™2017 https://www.nccn.org/evi-denceblocks/Accessed May 18, 2017
   Google Scholar
• Institute for Clinical and Economic ReviewICER value assessment framework. 2017 https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/Accessed May 18, 2017
   Google Scholar
• SMCRe-submission: olaparib, 50mg, hard capsules (Lynparza®) SMC No. (1047/15) AstraZeneca UK.UKScottish Medicies Consortium2016SMC No. 1047/15
   Google Scholar
• CloughJDKamalAHOncology care model: short- and long-term considerations in the context of broader payment reformJ Oncol Pract201511431932126060221
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services (CMS) [webpage on the Internet]The Quality Payment Program2016 [news release]; https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-10-25.htmlAccessed August 21, 2017
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS), Department of Health & Human ServicesThe Quality Payment Program Overview Fact Sheet2016 https://qpp.cms.gov/docs/Quality_Payment_Program_Overview_Fact_Sheet.pdfAccessed August 22, 2017
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS), Department of Health & Human Services [webpage on the Internet]Quality Payment Program2016 https://qpp.cms.gov/Accessed August 21, 2017
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS), Department of Health & Human ServicesThe Quality Payment Program [slide presentation]2016 https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/MACRA-MIPS-and-APMs/Quality-Payment-Program-Long-Version-Executive-Deck.pdfAccessed August 21, 2017
   Google Scholar
• DongLFPelizzariPM webpage on the InternetAdvanced APMs and Qualifying APM Participant Status2016 http://www.milliman.com/insight/2016/Advanced-APMs-and-Qualifying-APM-Participant-status/Accessed August 31, 2017
   Google Scholar
• Centers for Medicare & Medicaid Services. U.S. Department of JusticeMedicare Shared Savings Program ACO: Preparing to Apply for the 2018 Program Year [slide presentation]2017 https://www.cms.gov/Outreach-and-Education/Outreach/NPC/Downloads/2017-04-06-SSP-Presentation.pdfAccessed August 31, 2017
   Google Scholar
• U.S. Centers for Medicare & Medicaid Services (CMS) [webpage on the Internet]Oncology Care Model2017 https://innovation.cms.gov/initiatives/oncology-care/Accessed August 18, 2017
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS) [webpage on the Internet]Fact Sheets: Oncology Care Model2016 https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-06-29.htmlAccessed May 19, 2017
   Google Scholar
• (CMS) USCfMMSOncology Care Model: Key Drivers & Change Package https://innovation.cms.gov/Files/x/ocm-keydrivers-change-pkg.pdf962017Accessed September 28, 2017
   Google Scholar
• ChanAMcGregorSLiangWBUtilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: an analysis of 1655 patientsBreast201423567668225108452
   PubMed Web of Science ®Google Scholar
• AaproMCornesPAbrahamIComparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropeniaJ Oncol Pharm Pract201218217117921610020
   PubMedGoogle Scholar
• SunDAndayaniTMAltyarAMacDonaldKAbrahamIPotential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation studyClin Ther201537484285725704107
   PubMed Web of Science ®Google Scholar
• AaproMCornesPSunDAbrahamIComparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancerTher Adv Med Oncol2012439510522590483
   PubMed Web of Science ®Google Scholar
• GulacsiLBrodszkyVBajiPRenczFPentekMThe rituximab bio-similar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countriesAdv Ther20173451128114428397080
   PubMed Web of Science ®Google Scholar
• CesarecALikićRBudget impact analysis of biosimilar trastuzumab for the treatment of breast cancer in CroatiaAppl Health Econ Health Policy2016152277286
   Web of Science ®Google Scholar
• Farfan-PortetMIGerkensSLepage-NefkensIVinckIHulstaertFAre biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?Eur J Health Econ201415322322824271016
   PubMed Web of Science ®Google Scholar
• BocciaRJacobsIPopovianRde Lima LopesGJrCan biosimilars help achieve the goals of US health care reform?Cancer Manag Res2017919720528615973
   PubMed Web of Science ®Google Scholar
• Kyodo [webpage on the Internet]Generic Drugs to be Priced at 10% Less From AprilThe Japan Times Online2015 https://www.japantimes.co.jp/news/2015/12/02/national/science-health/generic-drugs-to-be-priced-at-10-less-from-april/#.Wal0irKGO1tAccessed September 8, 2017
   Google Scholar
• MominZWijayaCBernardoP webpage on the InternetWill Asia Go Big in Biosimilars Adoption and Manufacturing?Biosimilar Development 20175182017 https://www.biosimilardevelopment.com/doc/will-asia-go-big-in-biosimilars-adoption-and-manufacturing-0001Accessed September 8, 2017
   Google Scholar
• Japan Announces Proposed Plan to Reduce Biosimilar and Generic Drug Prices [webpage on the Internet]Big Molecule Watch2016 http://www.bigmoleculewatch.com/2016/02/03/japan-announces-proposed-plan-to-reduce-biosimilar-and-generic-drug-prices/Accessed September 8, 2017
   Google Scholar
• MulcahyAWPredmoreZMattkeSThe cost savings potential of biosimilar drugs in the United States [updated 2014] https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND_PE127.pdfAccessed June 14, 2017
   Google Scholar
• TaberneroJVyasMGiulianiRBiosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribersESMO Open201716e00014228848668
   PubMed Web of Science ®Google Scholar
• CohenHBeydounDChienDAwareness, knowledge, and perceptions of biosimilars among specialty physiciansAdv Ther201733122160217227798772
   PubMed Web of Science ®Google Scholar
• FelixAEGuptaACohenJPRiggsKBarriers to market uptake of biosimilars in the USGaBI J201433108115
   Google Scholar
• Market Wired [webpage on the Internet]Nearly half of US physicians say they will prescribe more biosimilars, according to new data from InCrowd [news release]2016 http://www.marketwired.com/press-release/nearly-half-us-physicians-say-they-will-prescribe-more-biosimilars-according-new-data-2102567.htmAccessed June 14, 2017
   Google Scholar
• MicklusAHot Topic: Biosimilars Market Access in the USDatamonitor Healthcare, Informa UK LimitedLondon, UK2017
   Google Scholar